The data are encouraging but early-stage and non-registrational; no PDUFA or pivotal trial readout is imminent. Traders should watch for initiation of Phase 3 trials for EIK1001 (TeLuRide-008) and any partnership or financing announcements. The stock's historical negative drift on prior neutral filings suggests limited near-term upside from these data alone.
Price Chart
Executive Summary
Eikon Therapeutics presented updated Phase 2 data for EIK1001 (TLR7/8 agonist) in first-line NSCLC at ASCO 2026, showing a 63.1% ORR and 90.8% DCR across 65 evaluable patients, with a manageable safety profile supporting outpatient administration. Initial Phase 1/2 data for EIK1003 (PARP1 inhibitor) showed a 24.5% ORR in combination with paclitaxel in heavily pretreated patients, though the stock has historically declined ~12% on prior neutral filings, suggesting limited market enthusiasm for early-stage data without a clear regulatory catalyst.
Key Facts
- EIK1001 (TeLuRide-005) Phase 2: 63.1% ORR and 90.8% DCR in 65 evaluable first-line NSCLC patients (non-squamous and squamous cohorts).
- EIK1001 safety profile: most TEAEs Grade 1-2; Grade 3+ TRAEs included neutropenia (30.6%), anemia (9.7%), thrombocytopenia (9.7%); all CRS events Grade 1-2.
- EIK1003 (Phase 1/2) monotherapy: 14.3% ORR overall, 26.7% in PARP-naïve patients; median DOR 7.8 months in 5 confirmed responders.
- EIK1003 + paclitaxel (Cohort 1C): 24.5% ORR in 53 evaluable patients (29.6% in platinum-resistant ovarian, 19.2% in breast cancer); 92% of responders had prior taxane therapy.
- No financial data (revenue, EPS, guidance) reported in this press release.
- Company is a late-stage clinical biopharma with no approved products; market cap ~$587M.
Financial Impact
No financial data provided; clinical data updates only.
Risk Factors
- EIK1001 and EIK1003 are investigational and may fail in later-stage trials.
- No revenue or approved products; company requires substantial additional funding.
- Competitive landscape: multiple TLR agonists and PARP inhibitors in development.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3303899 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | 8-K | $7.48 | awaiting T+20 | — | $6.68 (−10.66%) |
Oct 26, 2026 today | Press Release | $7.48 | awaiting T+20 | — | $6.68 (−10.66%) |
Oct 23, 2026 3d ago | 8-K | $8.01 | awaiting T+20 | — | $6.68 (−16.57%) |
Oct 7, 2026 18d ago | SC 13G/A | $7.54 | awaiting T+20 | — | $6.68 (−11.37%) |
Oct 2, 2026 23d ago | SC 13G/A | $7.33 | awaiting T+20 | — | $6.68 (−8.83%) |
Sep 22, 2026 4w ago | Institutional Cluster | $8.98 $8.18 | ▼ −8.91% | ▼ −8.35% | $6.68 (−25.58%) |
Sep 8, 2026 6w ago | Insider Buy | $10.73 $7.54 | ▼ −29.73% | ▼ −31.67% | $6.68 (−37.72%) |
Sep 3, 2026 7w ago | Press Release | $10.96 $8.04 | ▼ −26.64% | ▼ −25.52% | $6.68 (−39.03%) |
Aug 13, 2026 10w ago | 8-K | $11.05 $9.36 | ▼ −15.29% | ▼ −13.30% | $6.68 (−39.52%) |
Jul 20, 2026 14w ago | Press Release | $9.65 $10.47 | ▲ +8.50% | ▲ +4.38% | $6.68 (−30.75%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers